Answers are grounded in this paper and cite their sources.
Explores wet granulation for converting nanosuspensions into solid dosage forms, suggesting improved stability and compliance.
Background: The well-established biopharmaceutical advantages provided by nanosuspensions (NSs) make their conversion into solid oral dosage forms particularly appealing for improving both patients’ compliance and product stability. However, such a transformation continues to represent a significant challenge. Aim: This study explored manual wet granulation (WG) as a laboratory-scale strategy to transform an NS containing cinnarizine (CN) into granules, which were intended for direct administration or to be further processed. Methods: A range of polymers, characterized by different interaction mechanisms with aqueous fluids, were employed as carriers to incorporate the CN-containing NS during manual WG. The resulting granules were thoroughly characterized before tableting. Results: The NS-loaded products exhibited satisfactory physio-technological properties, effective nanocrystal redispersibility, high drug load efficiency, and expected in vitro performance. Moreover, they turned out to be suitable intermediates for mini-tablet production. Conclusions: Based on the data collected, WG turned out to be an effective lab-scale method for transforming an aqueous CN-containing NS into solid products (i.e., granules and mini-tablets), while preserving the starting properties of the drug nanocrystals. By adjusting formulation and process parameters, a variety of release kinetics were achieved, highlighting the value of the pursued approach, especially for early-stage screening of new drug candidates belonging to class II of the biopharmaceutical classification system.
No takes yet. Share an insight, caveat, or question.
Ragucci et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: